This analysis used propensity score matching of subjects from randomized placebo-controlled schizophrenia studies to compare paliperidone ER 6–12 mg/day with risperidone 2–4 mg/day and ...

Paliperidone (as palmitate) 1092mg/3.5mL, 1560mg/5mL; ext-rel susp for IM inj. Schizophrenia after adequately treated with Invega Sustenna (1-month paliperidone palmitate ext-rel inj susp) for at ...

J&J's current daily oral formulation, monthly injectable Invega Sustenna product and three-monthly depot Invega Trinza brought in sales of $1.9 billion in the first six months of this year.

That includes Johnson & Johnson's blockbuster Invega (paliperidone) range, which includes once-monthly (Invega Sustenna), three-monthly (Invega Trinza) and six-monthly version (Invega Hafyera), as ...

Background: To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology. Methods: Six double-blind ...